|
Indiana University
|
| Location |
Bloomington, Indiana, USA |
| Type |
Public Research University |
| Founded |
1820 |
| Website |
https://iu.edu/ |
| Focus Areas |
[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers), [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies), Neuroimaging |
| Medical School |
IU School of Medicine |
| Key Institute |
Stark Neurosciences Research Institute |
Indiana University (IU) is a public research university system with its flagship campus in Bloomington, Indiana. Founded in 1820, Indiana University has grown into one of the nation's largest and most comprehensive public research universities, with total enrollment exceeding 91,000 students across all campuses. The Indiana University School of Medicine, located in Indianapolis, is one of the largest medical schools in the United States and has established prominent research programs in neurodegenerative diseases, particularly Parkinson's disease, movement disorders, and Alzheimer's disease.
The university's commitment to neuroscience research is embodied in the Stark Neurosciences Research Institute, which serves as the umbrella organization for neuroscience research across the IU system. This institute brings together over 150 faculty members from multiple departments, creating a powerful ecosystem for understanding the mechanisms of neurodegeneration and developing novel therapeutic approaches.
¶ History and Development
¶ Founding and Early Years
Indiana University was founded in 1820 as the State Seminary of Indiana, making it one of the oldest public universities in the United States. The early curriculum focused on classical education, but the university rapidly expanded to include scientific and professional programs. The medical school was established in 1903, initially as a two-year program that later expanded to a full four-year curriculum.
The IU School of Medicine has grown to become one of the nation's largest medical schools, with over 1,800 medical students and 1,400 residents. The school maintains campuses throughout Indiana, enabling broad geographic coverage for clinical research and patient care. This distributed model has been particularly valuable for recruitment into clinical trials for neurodegenerative diseases.
The modern neuroscience research program at IU emerged in the 1970s and 1980s, with establishment of the Department of Neurology and growth of basic science programs in neurobiology. Key milestones include:
- 1970s: Establishment of the Movement Disorders Program
- 1990s: Creation of the Center for Neurodegeneration and Repair
- 2000s: Founding of the Stark Neurosciences Research Institute
- 2010s: NIH-funded Alzheimer's Disease Research Center established
- 2020s: Leadership in LRRK2 and alpha-synuclein research
The IU School of Medicine is the largest medical school in the United States by enrollment, with over 1,800 medical students across nine campuses throughout Indiana. The school has achieved national recognition for research funding, with annual research expenditures exceeding $350 million. Key departments include:
- Department of Neurology: Over 80 faculty members spanning all neurological subspecialties
- Department of Radiology: Advanced imaging research and clinical services
- Department of Pharmacology: Basic science research in neurodegeneration
- Department of Anatomy and Cell Biology: Developmental and cellular neuroscience
The Stark Neurosciences Research Institute serves as the coordinating body for all neuroscience research at IU. Key research centers include:
- Center for Neurodegeneration and Repair (CNR): Focus on disease mechanisms and therapeutic development
- Alzheimer's Disease Research Center (ADRC): NIH-funded center for AD research and clinical trials
- Parkinson's Disease Research Center: Comprehensive PD research program
The Department of Neurology provides comprehensive clinical care for neurodegenerative diseases while maintaining robust research programs. Clinical services include:
- Memory Disorders Clinic
- Movement Disorders Center
- Lewy Body Dementia Program
- ALS and Motor Neuron Disease Clinic
IU is one of the leading sites for Parkinson's disease research in the United States, with particular strength in:
¶ LRRK2 Genetics and Biology
LRRK2 mutations are the most common genetic cause of familial Parkinson's disease, and IU researchers have made major contributions to understanding LRRK2 biology. Research programs include:
- Genetic screening of Indiana populations for LRRK2 mutations
- LRRK2 kinase function and substrate identification
- Development of LRRK2 inhibitors for clinical use
- Biomarker development for LRRK2-targeted therapies
The Indiana Parkinson's Disease Registry, housed at IU, provides a valuable resource for genetic studies and clinical research.
Alpha-synuclein aggregation is the pathological hallmark of Parkinson's disease and related synucleinopathies. IU researchers investigate:
- Mechanisms of protein aggregation and propagation
- Strain diversity in synucleinopathies
- Development of seed amplification assays for diagnosis
- Therapeutic targeting of alpha-synuclein
IU researchers have been pioneers in deep brain stimulation (DBS) for Parkinson's disease. Current research includes:
- Optimization of stimulation parameters
- Novel targeting approaches
- Adaptive stimulation algorithms
- Outcomes research in DBS patients
The movement disorders surgery program at IU Health performs over 100 DBS procedures annually, making it one of the busiest centers in the Midwest.
The Alzheimer's Disease Research Center at IU maintains comprehensive research programs spanning basic science, translational research, and clinical trials.
IU researchers have contributed to the development of fluid biomarkers for Alzheimer's disease diagnosis and monitoring. Current research focuses on:
- Cerebrospinal fluid biomarker validation
- Blood-based biomarker development
- Neurofilament light chain as disease progression marker
- Multi-marker panels for patient stratification
The Center for Neuroimaging at IU provides state-of-the-art imaging capabilities for Alzheimer's disease research. Programs include:
- Amyloid PET imaging for early diagnosis
- Tau PET imaging for disease staging
- MRI for structural analysis and atrophy measurement
- Diffusion tensor imaging for white matter integrity
IU participates in numerous Alzheimer's disease clinical trials, including:
- Amyloid-targeting immunotherapies (lecanemab, donanemab)
- Tau-directed agents
- Neuroprotective compounds
- Lifestyle intervention studies
¶ Lewy Body Dementia Research
IU has established a strong program in dementia with Lewy bodies (DLB) research, a common neurodegenerative disease often underrecognized in clinical practice. Research areas include:
- Pathogenesis of DLB and relationship to Parkinson's disease
- Cognitive fluctuations in DLB and their underlying mechanisms
- Visual hallucinations and other DLB-specific symptoms
- Autonomic dysfunction in DLB
Growing program in FTD genetics, biomarkers, and clinical trials. IU participates in the ARTFL consortium for familial FTD research.
Clinical trials and genetic counseling programs through the HDSA Center of Excellence at IU.
¶ ALS and Motor Neuron Diseases
Research programs include:
- Biomarker discovery for disease monitoring
- Clinical trials of novel therapeutic agents
- Stem cell-based approaches
The Stark Neurosciences Research Institute provides state-of-the-art research facilities including:
- Cellular Imaging Core: Confocal and live-cell imaging
- Flow Cytometry Core: Single-cell analysis capabilities
- Proteomics Core: Mass spectrometry for biomarker discovery
- Animal Models Core: Transgenic and knockout mouse models
Advanced imaging facilities include:
- 3T and 7T MRI scanners
- PET/CT scanner dedicated to neuroscience research
- Cyclotron for radiotracer production
- Preclinical imaging for animal models
The clinical research infrastructure enables:
- Early-phase clinical trials
- Longitudinal observational studies
- Clinical registries and biobanking
- Telemedicine for remote patient monitoring
The Indiana Biobank provides researchers with access to:
- DNA samples from over 50,000 participants
- Longitudinal clinical data
- Linkage to electronic health records
- Dr. Ronald F. Pfenninger: Movement disorders specialist, pioneer in DBS surgery
- Dr. Thomas J. F. B.: LRRK2 genetics and PD biomarkers
- Dr. Joanna L.: Alpha-synuclein biology and seed amplification
- Dr. Martin R. Farlow: Leading AD clinical trialist, investigator on numerous Phase 2 and 3 studies
- Dr. Andrew J. Saykin: Neuroimaging researcher, leader in ADNI
- Dr. Hugh R.: Biomarker development and fluid diagnostics
¶ Lewy Body Dementia
- Dr. James E. Galvin: DLB researcher, developed cognitive assessment tools
- Dr. Connie W.: Clinical care and research in DLB and PD dementia
- Dr. M. W.: Neuroinflammation and microglia biology
- Dr. K. R.: Synaptic dysfunction in neurodegeneration
IU participates in numerous clinical trials for neurodegenerative diseases:
- LRRK2 inhibitors (DNL151, BIIB122)
- Alpha-synuclein-targeting therapies
- Disease-modifying agents
- DBS optimization studies
- Amyloid immunotherapies (lecanemab, donanemab)
- Tau-targeted agents
- Neuroprotective compounds
- Anti-inflammatory approaches
- ALS trials (tofersen, novel agents)
- Huntington's disease trials
- Frontotemporal dementia studies
- Neurology Residency: 4-year categorical program with rotation through all subspecialties
- Movement Disorders Fellowship: 1-year clinical and research fellowship
- Clinical Neurophysiology Fellowship: EMG and EEG training
- PhD in Neuroscience: Cellular, molecular, and systems neuroscience
- PhD in Medical Sciences: Interdisciplinary training
- MD/PhD Program: Combined clinical and research training
- NIH-funded postdoctoral positions
- Foundation fellowships
- Industry-sponsored research positions
- Michael J. Fox Foundation: Leadership in LRRK2 and alpha-synuclein research
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Contributing data and samples
- Parkinson's Progression Markers Initiative (PPMI): Participant enrollment
- Pharmaceutical company partnerships for clinical trials
- Device company collaborations for DBS research
- Diagnostic company partnerships for biomarker development
- International Parkinson's Disease Genetics Consortium
- European Alzheimer's Disease Consortium
- Global Alzheimer's Association Interactive Network
- LRRK2 Biomarkers: Development of phospho-LRRK2 assays for patient selection in clinical trials
- Alpha-Synuclein Seed Amplification: Validation of RT-QuIC assays for PD diagnosis
- Tau PET: Implementation of novel tau ligands for AD staging
- DBS Innovation: Development of directional DBS leads for improved outcomes
- Early work on levodopa metabolism in PD
- Pioneering studies in DBS for movement disorders
- Leadership in multi-center clinical trials for AD and PD
- Precision Medicine: Biomarker-guided patient selection for clinical trials
- Early Detection: Development of blood-based screening tests
- Disease Modification: Focus on LRRK2 and alpha-synuclein targeting
- Digital Health: Implementation of remote monitoring technologies
- Expansion of clinical trial infrastructure
- Enhanced neuroimaging capabilities
- Single-cell analysis core facility
- Indiana Neurodegeneration Research Network
- State-wide brain bank initiative
- Rural health outreach for clinical trials
IU offers diverse training pathways:
- Medical Student Research: Year-out research fellowships for medical students
- Graduate Programs: PhD in Neuroscience, Biochemistry, and Biomedical Engineering
- Postdoctoral Training: NIH-funded training positions in neurodegeneration
- Clinical Fellowships: Subspecialty training in movement disorders, cognitive neurology
IU researchers have published extensively in leading journals:
- Parkinson's disease genetics: Identification of novel risk loci in the PD population
- Biomarker development: Validation of blood-based markers for diagnosis
- Clinical trial design: Innovative approaches to adaptive trial designs
- Deep brain stimulation: Programming optimization and outcomes research